Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK08 live bacteria powder in diarrhea-predominant irritable bowel syndrome
CTR20210772Phase 2Completed
- Sponsor
- Zhiyi Pharmaceutics
- Start
- Apr 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SK08 in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Zhiyi Pharmaceutics. Started Apr 2021; status: completed.
02
Drugs
SK08
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on CTR20210772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210772.